Harnessing Continuous Glucose Monitors for Type 1 Diabetes Management + Closing Words

Robert Gabbay, MD, PhD, gives closing thoughts and advocates that continuous glucose monitors should be supplied for all insulin-dependent diabetes patients, including at initial diagnosis, to facilitate self-management and tighter control of this disease.

EP: 1.Unraveling Type 1 Diabetes: Differences Between Type 1 and Type 2

EP: 2.Early-stage Type 1 Diabetes and The Psychological Impact of Progressing to Stage 3

EP: 3.Identifying Risk to Enable Early Detection of Type 1 Diabetes

EP: 4.Challenges in Autoantibody Screening for Type 1 Diabetes

EP: 5.Strategies for Preventing Progression of Early-Stage Type 1 Diabetes

EP: 6.Optimal Approaches to Diagnostic Testing for Type 1 Diabetes Mellitus

Now Viewing

EP: 7.Harnessing Continuous Glucose Monitors for Type 1 Diabetes Management + Closing Words

Related Videos

Related Content

Advertisement

December 2nd 2024

CMS, HHS Finalize Mandatory Model to Boost Kidney Transplant Access, Equity

Brooke McCormick

The 6-year mandatory Increasing Organ Transplant Access Model aims to boost kidney transplants and address disparities by incentivizing hospitals, enhancing care coordination, and measuring transplant outcome performance.

October 29th 2024

Breaking the Cycle: The Importance of Early Intervention in Hidradenitis Suppurativa

Giuliana Grossi

Prompt care supports mental well-being, as hidradenitis suppurativa is often associated with depression and anxiety due to its physical and social challenges.

December 2nd 2024

Baseline Response Rates Inform Immunotherapy Sequencing in NSCLC

Maggie L. Shaw

Investigators were seeking clarification on optimal sequencing of the immune checkpoint inhibitor atezolizumab following treatment failure and disease progression after receipt of nivolumab and pembrolizumab.

July 18th 2024

Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.

November 29th 2024

sGFAP May Predict Progression Independent of Relapse in BCDT-Treated MS

AJMC Contributor

The findings show that increases in serum glial fibrillary acidic protein throughout B-cell depletion therapy are associated with disability worsening despite not relapsing—known as progression independent of relapse activity.

November 29th 2024

Authors Identify Monoclonal Antibody to Selectively Target CALR Mutations in MPNs

Mary Caffrey

A decade after the discovery of CALR, the results are the first for a possible therapy for CALR-mutated MPNs to reach the clinic.

Related Content

Advertisement

December 2nd 2024

CMS, HHS Finalize Mandatory Model to Boost Kidney Transplant Access, Equity

Brooke McCormick

The 6-year mandatory Increasing Organ Transplant Access Model aims to boost kidney transplants and address disparities by incentivizing hospitals, enhancing care coordination, and measuring transplant outcome performance.

October 29th 2024

Breaking the Cycle: The Importance of Early Intervention in Hidradenitis Suppurativa

Giuliana Grossi

Prompt care supports mental well-being, as hidradenitis suppurativa is often associated with depression and anxiety due to its physical and social challenges.

December 2nd 2024

Baseline Response Rates Inform Immunotherapy Sequencing in NSCLC

Maggie L. Shaw

Investigators were seeking clarification on optimal sequencing of the immune checkpoint inhibitor atezolizumab following treatment failure and disease progression after receipt of nivolumab and pembrolizumab.

July 18th 2024

Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.

November 29th 2024

sGFAP May Predict Progression Independent of Relapse in BCDT-Treated MS

AJMC Contributor

The findings show that increases in serum glial fibrillary acidic protein throughout B-cell depletion therapy are associated with disability worsening despite not relapsing—known as progression independent of relapse activity.

November 29th 2024

Authors Identify Monoclonal Antibody to Selectively Target CALR Mutations in MPNs

Mary Caffrey

A decade after the discovery of CALR, the results are the first for a possible therapy for CALR-mutated MPNs to reach the clinic.